NDAINJECTIONINJECTABLE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
DEPACON (valproate sodium) by AbbVie is blood. Approved for women, women of childbearing potential. First approved in 1996.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEPACON (valproate sodium) is an intravenous anticonvulsant approved in 1996 for seizure management and acute mania. The drug's mechanism is not fully established but is thought to work by increasing brain concentrations of gamma-aminobutyric acid (GABA), enhancing neuronal inhibition. It is indicated primarily for women and women of childbearing potential, reflecting safety considerations around teratogenicity.
LOE Approaching
As LOE approaches, the brand team will likely shrink; commercial roles are consolidating around cost management and generic transition planning.
Mechanism of Action
blood. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).
Indications (2)
Clinical Trials (1)
An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.
Started Jul 2003
15 enrolled
Cluster Headache
Worked on DEPACON at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.